Gary Mendese, MD
MOHS-Micrographic Surgery · Dover, NHNPI 1780851386
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,385 of the $4,504 with a category attached, or 75.2%. 20 manufacturers reported payments, led by Mimedx Group, Inc. at 33.7% of the total. Reporting peaked in 2024 at $1,578 and has fallen 97.5% since, to $40 in 2025.
Across 125 payments — averaging $36.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mimedx Group, Inc.$2K
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$315
- Novartis$216
- Johnson & Johnson$185
- Lilly USA, LLC$173
- plus $667 from 14 others
Across 4 payments — averaging $20,774 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$83K
What the payments were for
- Travel & lodging$93721%
- Food & beverage$3,38575%
- Education$1824%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mimedx Group, Inc. | 8 | $1,518 |
| AbbVie(2 entities) | 58 | $1,431 |
| Sun Pharmaceutical Industries Inc. | 9 | $315 |
| Novartis | 9 | $216 |
| Johnson & Johnson | 8 | $185 |
| Lilly USA, LLC | 5 | $173 |
| Galderma Laboratories, L.p. | 4 | $157 |
| Strata Skin Sciences, Inc. | 8 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $76 |
| Genentech USA, Inc. | 2 | $48 |
| Bristol Myers Squibb | 2 | $42 |
| UCB, Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 1 | $36 |
| Organon | 2 | $34 |
| Organogenesis Inc. | 1 | $30 |
| Amgen | 1 | $24 |
| Sanofi | 1 | $23 |
| Pfizer | 1 | $22 |
| Incyte Corporation | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few mohs-micrographic surgery providers in New Hampshireto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 21 | $108 |
| Mupirocin | 11 | $88 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Dover
- Daniel O'ConnorDover$247
- Mollie MaccormackNashua$6K
- Brienne CresseyStratham$2K
- Catherine PisanoPortsmouth$1K
- Hamad AlabdulrazzaqManchester$765
- Shayna RivardWolfeboro$252
- Daniel StewartManchester$181
- Manuel IriondoLebanon$178
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.